Introduction
The aryl hydrocarbon receptor (AhR), along with its nuclear binding partner AhR nuclear translocator (ARNT) (Denison and Nagy, 2003) , is a ligandactivated transcription factor of the basic helix-loophelix Per-Arnt-Sim (PAS) family of transcriptional regulators. These proteins are characterized by two conserved domains, the N-terminal basic helix-loophelix domain and the PAS domain, which spans two hydrophobic repeats termed PAS-A and PAS-B. The functional effects of AhR activation have been elucidated using ligands of toxicological concern, such as the polycyclic aromatic hydrocarbon benzo [a] pyrene, and a variety of halogenated aromatic hydrocarbons, known as environmental toxins. Of the latter group of chemicals, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is the most potent AhR agonist, because of its high binding affinity and resistance to metabolism (Poland and Knutson, 1982) . On ligand binding, AhR accumulates in the nucleus where it forms a transcriptionally active complex with ARNT. This heterodimer interacts with a 5 0 -GCGTG-3 0 DNA sequence, the core binding motif of the xenobiotic response or dioxin response elements (DRE) (Fujisawa-Sehara et al., 1987) , which are located in regulatory regions of a network of genes that encode drug metabolizing enzymes, such as cytochrome P450 1A1 (CYP1A1) and CYP1A2 (Gu et al., 2000) . Thus, when first discovered, AhR was regarded as a pathway regulating the induction of CYP1A1 and the related enzymes (Poland et al., 1976; Poland and Knutson, 1982) . Thereby, oxidative metabolic processes are induced that mediate the toxicity of dioxin-like compounds (Shimizu et al., 2000) . The wide range of toxic effects induced by these compounds, including birth defects, impaired reproductive capacity and altered immune responses, have encouraged research on the interaction of AhR with sex steroid receptors and the immune system (Ohtake et al., 2008; Quintana et al., 2008; Veldhoen et al., 2008) . AhR regulates cellular differentiation during development (Huang et al., 2004; Lahvis et al., 2000) and may promote cell cycle progression in the absence of exogenous ligand (Chang et al., 2007; Marlowe and Puga, 2005) . There is also an emerging evidence for a prominent role of AhR in tumorigenesis. AhR overexpression induces the development of tumors in the glandular part of the stomach and in the liver in transgenic mice (Andersson et al., 2002; Moennikes et al., 2004) . More importantly, the AhR repressor, which functions as a dominant-negative AhR inhibitor, is silenced in multiple human tumor types by DNA promoter hypermethylation (Zudaire et al., 2008) .
A role of AhR in glioblastoma has not been elucidated yet. This tumor type is highly lethal with a median survival of 7-9 months in population-based studies (Ohgaki et al., 2004) . High transforming growth factor-b (TGF-b)/Smad activity is typical for these aggressive tumors and confers a poor prognosis (Bruna et al., 2007) . Depleting TGF-b by RNA interference or antagonizing the TGF-b receptor I kinase, which mediates Smad2 signaling, both inhibit growth and invasiveness and enhance the immunogenicity of murine and human glioma cells in vitro and in vivo (Friese et al., 2004; Uhl et al., 2004) . Importantly, AhR and TGF-b signaling pathways are known to cross-regulate each other in a cell type-specific manner (Chang et al., 2007; Wolff et al., 2001) . Moreover, latent TGF-b-binding protein-1 (LTBP-1), a protein that has been characterized as crucial in the process of TGF-b activation in gliomas (Tritschler et al., 2009) , is a transcriptional target of AhR (Corchero et al., 2004; Santiago-Josefat et al., 2004) . Altogether, the possible interplay of these important factors led us to study the role of AhR in glioma cells in more detail.
Results

Human malignant glioma cells express AhR in vitro
Real-time PCR showed heterogeneous AhR mRNA expression levels in 12 established glioma cell lines, the four primary glioma cell cultures TU132, TU140, TU323 and TU325, and the sv40-transformed nonneoplastic astrocytic cell line, sv-FHAS. The highest mRNA levels were found in LNT-229, T98G, D247MG and LN-319 cells. Conversely, AhR expression was rather low in U138MG, U251MG, U373MG and sv-FHAS cells (Figure 1a) . The AhR protein levels were determined in the same panel of cell lines by immunoblot. AhR migrated as an apparent double band at 80-110 kDa. The predicted molecular weight is B100 kDa. To determine the specificity of the proteins bands detected by this AhR antibody, a small interfering RNA (siRNA)-mediated AhR knockdown was carried out in LN-308 cells. The lower protein band was not affected by siRNA treatment, whereas the upper band of around 100 kDa was strongly reduced (Figure 1b, left panel) . Taking the results of the knockdown experiments into account, U87MG, D247MG, LN-319 and LN-308 cells had the highest AhR protein expression levels. Low AhR protein levels were found in U138MG, U251MG, U373MG and A172 glioma cells, in accordance with the mRNA data. Immunocytochemistry of the glioma cell line, LNT-229, showed a predominantly cytoplasmatic staining of the AhR protein (Figure 1c) . Application of the synthetic AhR ligand 3-methylcholanthrene (3-MC), which is a paradigmatic AhR agonist (Mimura and Fujii-Kuriyama, 2003) , induced translocation of AhR into the nucleus, confirming the responsiveness of these cells to exogenous AhR ligands.
Pharmacological and genetic modulation of AhR activity in glioma cells
We selected five glioma cell lines, LN-18, T98G, U87MG, LNT-229 and LN-308, with varying AhR protein expression levels for further studies and the immortalized fetal astrocyte cell line, sv-FHAS, for comparison. After transient transfection with the artificial CYP1A1 reporter construct pT81/3 Â DRE, the cells were treated with 10 mm CH-223191, an AhR receptor antagonist, which potently inhibits TCDDinduced AhR-dependent transcription and blocks the binding of TCDD to AhR (Kim et al., 2006) . CH-223191 decreased DRE reporter activity of all respective glioma cell lines at 10 mM (Figure 2a ). Higher concentrations of up to 25 mM CH-223191 did not provide a stronger inhibition of pT81/3 Â DRE reporter activity (data not shown). Further, the cells were exposed to 3-MC, which induces DRE reporter activity at this concentration in other models (Ohtake et al., 2003) . The pT81/3 Â DRE reporter was inducible by 3-MC in all glioma cell lines tested, as well as in the human astrocytic cell line. The highest levels of induction were obtained in LN-308 and in sv-FHAS cells (2.1-fold and 2.7-fold, respectively). For all further experiments, concentrations of 10 mM CH-223191 and 1 mM 3-MC were chosen.
The LNT-229 and LN-308 glioma cell lines were chosen for a transient knockdown of AhR. AhR mRNA levels were reduced to 10% at 48 h after transfection (data not shown) that resulted in a reduction of DRELuc reporter activity to 30% in LNT-229 and to 13% in LN-308 cells. Stimulation with CH-223191 or 3-MC for 20 h still modulated DRE reporter activity, but to a reduced extent (Figure 2b ). Plasmid-mediated gene transfer was then used to express a constitutive active AhR (CA-AhR) with a minimal deletion in the PAS-B domain in LNT-229 glioma cells. This AhR mutant has been reported to localize to the nucleus, heterodimerize with ARNT, and activate transcription by binding xenobiotic response element sequences in a ligandindependent manner (McGuire et al., 2001) . Expression of the transgene in the LNT-229 transfectant pools was determined by PCR analysis with primers specific for CA-AhR that do not amplify wild-type AhR. CA-AhR mRNA was detected in all five LNT-229 transfectant pools, but not in the control-transfected LNT-229 cells (Figure 2c ). Unexpectedly, there was no elevation of DRE reporter activity in the respective LNT-229/CAAhR pools #1 to #5. Only co-transfection of the DRE reporter with the AhR binding partner ARNT showed strong induction of reporter activity for all LNT-229/ CA-AhR pools, suggesting that low ARNT levels are a limiting factor for AhR activity in this cell line ( Figure 2c) .
Next, mRNA expression levels of the AhR-responsive gene, CYP1A1, were determined in glioma cells exposed to CH-223191 and 3-MC. CH-223191 did not decrease CYP1A1 mRNA levels in U87MG and even induced CYP1A1 mRNA expression in LN-18 cells. In these cell lines 3-MC strongly increased CYP1A1 mRNA levels. CH-223191 reduced CYP1A1 mRNA levels very efficiently in T98G and LNT-229 cells, but these cell lines were not inducible by 3-MC (Figure 2d ). LNT-229 and LN-308 cells were chosen for time-course experiments and stimulated with CH-223191 or 3-MC for 20, 48 or 72 h. CYP1A1 mRNA expression was inhibited by CH-223191 up to 80% in LNT-229 and up to 97% in LN-308 at 72 h. 3-MC induced CYP1A1 mRNA levels for LN-308 at all time points, peaking at 48 h after treatment. In LNT-229 cells, 3-MC did not substantially induce CYP1A1 mRNA levels and even lowered them at longer incubation periods of 48 and 72 h (Figure 2e ). This response pattern may result from a negative feedback loop of AhR stimulation attributed to the promotion of AHR degradation (Ohtake et al., 2007) . AhR gene silencing diminished CYP1A1 mRNA expression in both cell lines (Figure 2f) . Analysis of the CYP1A1 mRNA expression levels in the five LNT-229/CA-AhR transfectant pools showed unchanged and in three out of five pools even lower CYP1A1 mRNA levels. As expected from the results of the DRE-Luc experiments in these cell lines (Figure 2c) , transfection of ARNT, however, strongly increased CYP1A1 mRNA levels for all pools (Figure 2g ). This is in line with the lack of CYP1A1 inducibility in LNT-229 by 3-MC as described in Figure 2e , and again may be because of the limiting endogenous ARNT levels.
Human malignant gliomas express AhR in vivo Normal human brain and gliomas of WHO grades II-IV were examined for AhR expression by immunohistochemistry. The expression pattern of AhR in normal brain and in gliomas was heterogeneous. The following brain regions from 23 brain autopsies were stained: cortex and white matter of frontal, parietal, temporal and occipital lobe, basal ganglia, thalamus, hippocampus, midbrain and cerebellum. There was no AhR expression in pyramidal hippocampal neurons, nigral neurons of the midbrain, pyramidal cortical neurons or granular cerebellar cells. A strong expression was seen in astrocytes, for example, of the hippocampus (Figure 3a) . AhR expression in glioblastomas ranged from no expression to very strong staining (Figure 3b ). Although expression was observed in the cytoplasm and nuclei of glial cells, endothelial cells of proliferating vessels were AhRnegative. The expression intensity of AhR in the nuclei was stronger in almost all cases than in the cytoplasm. In pseudopalisading tumor cells bordering necrotic tumor parts, AhR showed stronger immunoreactivity than in other tumor parts. Sometimes macrophages in the necrotic zone of glioblastomas were AhR-positive.
The mean expression levels (percentage of AhRpositive tumor cells) showed a decrease from WHO grade II astrocytomas (mean 32.67; 95% confidence interval (CI) 24.6-40.75) to lower levels in grade III anaplastic astrocytomas (mean 25.75; , and lowest levels in grade IV glioblastoma (mean 17.34; . The difference in the expression levels was significant for grade II gliomas compared with grade IV gliomas (P ¼ 0.0018, Figure 3c ).
In contrast to the expression levels, the nuclear staining intensity increased in 86 WHO grade IV Pharmacological modulation of AhR alters LTBP-1, TGF-b1 and TGF-b2 protein levels Next, we investigated the role of AhR for the synthesis, release and activity of TGF-b1 and TGF-b2. In a pharmacological approach, we used the same concentrations of CH-223191 and 3-MC, which had been titrated in the DRE reporter assays, and determined LTBP-1, TGF-b1 and TGF-b2 protein levels in the conditioned media of LNT-229 cells (Figure 4a ). There was a reduction of LTBP-1 at 48 h, and of the proform (50 kDa) and active (12.5 kDa) form of TGF-b1 at 72 h. In contrast, 3-MC did not modulate the expression levels of these proteins. We verified our observations by investigating a panel of established and primary glioma cells and the immortalized astrocytic cell line, sv-FHAS. CH-223191 strongly reduced the protein levels of 12.5 kDa TGF-b and LTBP-1 at 72 h in LN-18, U87MG, LN-308 and the primary cell culture, TU323. Similarly, the TGF-b proforms of LN-18, U87MG and TU323 cells were reduced. The effect was less prominent and restricted to LTBP-1 for TU132 (Figure 4b) . Interestingly, this cell line had little AhR expression ( Figure 1a and b) , confirming the specificity of our approach. The sv-FHAS cells responded differently than all glioma cell lines in that CH-223191 elevated protein levels of LTBP-1, TGF-b1, and TGF-b2. For all the established and primary glioma cells, 3-MC did not influence protein levels of LTBP-1, TGF-b1 and TGF-b2, except for an increase of LTBP-1 protein levels in LN-18 and U87MG cells. As exposure to 3-MC induced the loss of AhR protein, presumably through the degradation as shown here for LN-308 cells (Figure 4b ), the constitutive overexpression of CAAhR seemed to be a more suitable model for further studies (see below). In line with the reduction of TGF-b in the conditioned media, a reduction of Smad2 phosphorylation was observed in LNT-229 and LN-308 cells exposed to CH-223191 at 48 and 72 h, as well as for U87MG and TU323 cells at 72 h after treatment. In contrast, sv-FHAS cells responded to CH-223191 with increased Smad2 phosphorylation (Figure 4b ).
Genetic modulation of AhR influences Smad2
phosphorylation by influencing LTBP-1, TGF-b1 and TGF-b2 protein levels The biological effects of CH-223191 on the TGF-b system were reproduced using a genetic approach. AhR gene silencing led to a decrease in LTBP-1, TGF-b1 and TGF-b2 protein levels. Phosphorylated Smad2 (pSmad2) levels in cellular lysates also declined in both cell lines (Figure 5a ). Conversely, pSmad2 levels were increased in LNT-229 cells stably expressing CA-AhR, as were LTBP-1 and TGF-b2 levels, although TGF-b1 protein levels remained unchanged (Figure 5b ). Increased intracellular TGF-b signaling was detected for all LNT-229/CA-AhR pools (Po0.01) by using the pGL3-SBE-4 reporter plasmid, which detects transcriptional activity of TGF-b1/2 (Figure 5c ).
We also analysed changes in mRNA levels in response to the different approaches of AhR modulation, to assess the contribution of transcriptional regulation to the changes in the TGF-b system observed here. Exposure to CH-223191 resulted in decreased mRNA levels of LTBP-1 (up to 90% decrease), TGF-b1 (up to 70% decrease) and TGF-b2 (up to 60% decrease) in LN-308 cells. Performing a time-course analysis, we did not observe such changes in the respective mRNA levels in LNT-229 cells. Further, AhR gene silencing with a strong reduction of AhR mRNA to 10% did not affect LTBP-1, TGF-b1 or TGF-b2 mRNA levels (data not shown). Consistent with the protein data (Figure 5c ), LNT-229/CA-AhR cell pools showed increased levels of LTBP-1 (two-to sevenfold increase for all pools) and TGF-b2 mRNA, in which mRNA levels peaked at 30-fold induction for pool #1-and 70-fold induction for ), and phosphorylated Smad2 (pSmad2), total Smad2/3, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and AhR protein levels were detected in whole cell lysates by immunoblot analysis.
AhR regulates TGF-b/Smad/LTBP-1 in gliomas D Gramatzki et al pool #3, respectively. Interestingly, TGF-b1 mRNA levels were unaltered. Again, transient co-expression of ARNT in the LNT-229/CA-AhR pools also led to an increase of TGF-b1 mRNA levels (two-to sixfold).
Changes in AhR activity modulate glioma cell proliferation, clonogenic survival and invasiveness Incorporation assays were carried out using 5-bromo-2-deoxyuridine to determine whether the modulation of As AhR has been reported to be involved in cell cycle control (Elferink, 2003) , cell cycle analyses were carried out in LNT-229 and LN-308 cells exposed to CH-223191 or 3-MC. There were no specific redistributions between the relative populations in G0/1, S or G2/M phase in LNT-229 cells, but a decrease in the G0/1 and a concomitant increase in the subG0/1 and S phase in response to 3-MC (Table 1) was observed in LN-308 cells, indicating a minor induction of cell death.
In view of a possible application of AhR antagonism as a therapeutic concept for malignant gliomas, we also analysed the effects of AhR inhibition on the clonogenicity of these cells. A brief 24 h exposure to CH-223191 decreased clonogenic survival by 56% in LNT-229 and by 66% in LN-308 cells. AhR gene silencing in LNT-229 led to decreased clonogenic survival by 46%, whereas overexpression of CA-AhR promoted clonogenicity and thus the malignant phenotype (Figure 7a ). Representative images of clonogenic survival after exposure to CH-223191 in LNT-229 and LN-308 cells are shown in Figure 7b .
We also determined whether CH-223191 targets invasiveness, another important biological determinant of malignancy. Figures 7c and d show that CH-223191 reduced invasiveness of the LNT-229 cell line by 81% and of the LN-308 cell line by 72%.
Discussion
This study identifies AhR as a mediator of the malignant phenotype of human glioma cells and a potential target for the treatment of these tumors. We confirmed AhR expression at the mRNA and protein level in a variety of human long-term glioma cell lines as well as primary glioma cells, and demonstrated the responsiveness of AhR at the level of induced nuclear translocation (Figure 1 ). Almost all assays carried out here indicated that AhR promotes the malignant phenotype of glioma cells, as defined at the level of proliferation, clonogenicity and invasiveness, as exposure to the AhR antagonist CH-223191 or AhR gene silencing interfered with these properties (Figures 6 and 7) . TGF-b has been identified as crucial factor in the malignant phenotype of glioblastomas (Weller and Fontana, 1995; Wick et al., 2001) and as a downstream target of AhR signaling (Haarmann-Stemmann et al., 2008) . In non-malignant cells of AhR null mice, the LTBP-1/TGF-b pathway by AhR is regulated by diverse mechanisms. These include post-translational regulatory mechanisms, as described for primary hepatocytes (Zaher et al., 1998) , regulation of mRNA levels (Chang et al., 2007) and cytokine activation in the extracellular matrix of embryonic fibroblasts (Gomez-Duran et al., 2006) . The fact that LTBP-1 may activate TGF-b in the absence of altering total TGF-b levels in LN-308 cells (Tritschler et al., 2009 ) adds complexity to this issue. The putative link between AhR and TGF-b and its functional regulator, LTBP-1, provided the initial rationale for this study. Exposure to the AhR antagonist CH-223191 proved to be a reliable measure to decrease the levels of TGF-b and LTBP-1 in glioma cells and, as the important functional readout, cellular pSmad2 levels (Figures 4 and 5) . The latter have been characterized as a striking negative prognosticator in human glioma patients (Bruna et al., 2007) . Conversely, constitutive overexpression of CA-AhR in LNT-229 cells led to an increase of LTBP-1 and TGF-b2 protein levels, resulting in enhanced intracellular TGF-b signaling as indicated by increased pSmad2 levels ( Figure 5b ) and enhanced TGF-b reporter activity (Figure 5c ).
The non-neoplastic astrocyte cell line, sv-FHAS, was used for comparison to determine whether there are differences in AhR function in glioma cells, which are characteristic of their malignant phenotype. Interestingly, sv-FHAS was responsive to 3-MC by reporter activity (Figure 2a ) also. However, LTBP-1, TGF-b1 and TGF-b2 protein levels were upregulated rather than downregulated in response to CH-223191 (Figure 4) . A negative regulation of the LTBP-1/TGF-b system by 
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AhR has been reported earlier, for example, for embryo fibroblasts and primary hepatocyte cultures using the paradigm of AhR null mice (Santiago-Josefat et al., 2004; Zaher et al., 1998) . Regulators of TGF-b signaling have been reported earlier to function abnormally, and thus influence the progression of tumors such as glioblastoma (Miyazono et al., 2003; Seoane et al., 2004) . Distinct patterns of gene expression between tumor cells derived from liver or brain have been described earlier (Maier et al., 2007) . Importantly, we unrevealed AhR as a positive regulator of the LTBP-1/ TGF-b axis in glioblastomas in contrast to its earlier reported negative role in other non-malignant cell systems. LNT-229 and LN-308 were characterized in more detail to illustrate common and variable aspects of AhR function in glioma cells. Both cell lines responded to CH-223191 with decreased DRE reporter activity (Figure 2 ). CH-223191 decreased mRNA levels of LTBP-1, TGF-b1 and TGF-b2 in LN-308 cells, which release high levels of these proteins, but not in LNT-229 cells, which release low levels of these proteins and whose malignant phenotype may be less dependent on this pathway. AhR gene silencing reduced pSmad2 levels in both cell lines, suggesting complex regulatory mechanisms of the AhR on LTBP-1, TGF-b1 and TGF-b2 protein levels beyond transcriptional regulation.
Overall AhR gene silencing was a less powerful measure than pharmacological inhibition using CH-223191, which as a small molecule inhibitor is applied in great excess and directly targets the AhR protein. Thus, we assume that different activities of AhR are differentially sensitive to inhibition in glioma cells in a cell line-specific manner, presumably as a result of AhR co-regulation by multiple other pathways with partial redundancy.
In contrast to LN-308 cells, CYP1A1 mRNA expression in LNT-229 cells was not 3-MC-inducible (Figure 2 ). This was probably because of the limited availability of the AhR co-factor, ARNT, as forced expression of CA-AhR by stable plasmid-mediated gene transfer increased DRE reporter activity in this cell line only when ARNT was co-expressed (Figure 2) . Finally, to predict the possible value of targeting AhR in human glioma patients in vivo, we studied AhR expression in normal brain and in a large series of human gliomas using immunohistochemistry (Figure 3) . AhR was broadly expressed among the tumors, but the expression patterns showed some peculiar features, which might have relevance for the understanding of the role of AhR in the malignant progression of these tumors. There was a trend for a lower frequency of AhR-expressing cells with increasing grade of malignancy, which was associated with a significant increase of nuclear staining intensity in high-grade lesions. Further studies will need to clarify how these patterns translate into AhR activity, and whether the expression of AhR in glioblastomas in vivo is a stable feature of the labeled cells or modulated, for example, by cell cycle progression, hypoxia or prior treatment. Further, the studies of LNT-229 cells reported here suggest that other factors including not only ARNT, but also a series of transcriptional co-activators and co-repressors might determine AhR function in gliomas in vivo (Harper et al., 2006) . Among these, the AhR repressor has attracted particular attention. AhR repressor represses the transcriptional activity of AhR by competing for ARNT functioning as a naturally occurring dominantnegative factor. It has been described as a putative tumor suppressor gene, and its expression is lost in multiple human tumor types by DNA hypermethylation, although gliomas have not been studied yet (Zudaire et al., 2008) .
In summary, this study defines AhR signaling as a central switch to a malignant phenotype in malignant glioma cells which controls proliferation, clonogenicity, invasiveness and the TGF-b pathway. Genetic or pharmacological efforts at exploiting AhR modulation as a therapeutic target for glioblastoma, one of the most fatal human malignancies, are warranted.
Materials and methods
Cells and reagents
The human malignant glioma cell lines, U87MG and T98G, and NIH-3T3 murine fibroblasts, were obtained from the American Type Culture Collection (Rockville, MD, USA). LN-18, U138MG, LN-428, D247MG, LN-319, LNT-229, A172, U251MG, U373MG and LN-308 cells were kindly provided by N de Tribolet (Lausanne, Switzerland). In contrast to other LN-229 sublines, LN-229 glioma cells cultured in our laboratory retained wild-type p53 status and were renamed LNT-229. All primary glioblastoma cells, TU132, TU140, TU323 and TU325, were established from freshly resected tumors and used during the first passages. The human sv-FHAS astrocytic cell line was provided by D Stanimirovic (Institute for Biological Sciences, Ottawa, Canada). The cells were maintained in phenol red-free Dulbecco's modified Eagle's medium (Lonza, Verviers, Belgium) containing 10% fetal calf serum (Biochrom KG, Berlin, Germany). For all experiments described herein, the cells were allowed to attach over a 24-h period. Subsequently all experiments were carried out in phenol red-free medium without serum. siRNA pools targeting AhR, TGF-b1 or TGF-b2, containing four selected siRNA duplexes each with a modification pattern that addresses off-target effects caused by both strands (ON-TARGETplus SMARTpool) and the non-targeting control pool (ON-TARGETplus siCONTROL non-targeting pool) were purchased from Dharmacon (Lafayette, CO, USA) and used at 100 nM. The siRNA pool targeting AhR had the following duplex sense sequences: 5 0 -GCAAGUUAAUGGCA UGUUU-3 0 , 5 0 -GAACUCAAGCUGUAUGGUA-3 0 , 5 0 -GC ACGAGAGGCUCAGGUUA-3 0 and 5 0 -GCAACAAGAUG AGUCUAUU-3 0 . The siRNA pool targeting TGF-b1 had the duplex sense sequences 5 0 -AUUGAGGGCUUUCGCCUUA UU-3 0 , 5 0 -CCGAGAAGCGGUACCUGAAUU-3 0 , 5 0 -GCAG AGUACACACAGCAUAUU-3 0 and 5 0 -GTGACUAUCCAC CUGCAAGAUU-3 0 . Sequences of the siRNA pool targeting TGF-b2 were duplex sense sequences 5 0 -GGAUUGAGCUA UAUCAGAUUU-3 0 , 5 0 -CUGCGUGUCCCAAGAUUUAU U-3 0 , 5 0 -GAUGCGGCCUAUUGCUUUAUU-3 0 and 5 0 -GA GCAUGCCCGUAUUUAUGUU-3 0 . Stable and transient lipophilic transfection was carried out with Metafectene Pro (Biontex, Martinsried, Germany). Recombinant human TGF-b1 and TGF-b2 and monoclonal anti-human LTBP-1 antibody (clone MAB388) were purchased from R&D Systems (Minneapolis, MN, USA). The mouse monoclonal antibodies to AhR, clone RPT1 suitable for immunoblotting and clone RPT9 suitable for immunocytochemistry were purchased from Abcam (Cambridge, UK), The rabbit polyclonal antibody to AhR used for immunohistochemistry was obtained from Acris (Acris, Hiddenhausen, Germany). Rabbit polyclonal antibody to TGF-b2 was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). TGF-b1 and phospho-Smad2 (Ser465/467) (clone 138D4) antibodies were purchased from Cell Signaling Technology (Boston, MA, USA), the Smad2/3 antibody (clone18) was purchased from BD Bioscience (New York City, NY, USA). The antibody to glyceraldehyde 3-phosphate dehydrogenase was obtained from Chemicon (Temecula, CA, USA). CH-223191, 2-methyl-2H-pyrazole-3-carboxylic acid ((2-methyl-4-O-tolylazo-phenyl)-amide) was purchased from Merck (Darmstadt, Germany). 3-MC was obtained from Sigma Aldrich (St Louis, MO, USA). Stable AhR transfectants were obtained by transfection using pCA-Ahr/cytomegalovirus (CMV) 4 (McGuire et al., 2001) . Expression of the CA-AhR construct was verified by PCR with specific primers (Ito et al., 2004) .
Immunocytochemistry
Cells were cultured in chamber slides with polystyrene treated glass (BD Falcon, San Jose, CA, USA). Medium was removed after 24 h and cells were treated in serum-free medium with the respective reagents. After 5 h, cells were washed with phosphate buffered saline and fixed with ice-cold methanol: acetone (1:1). Cells were washed with 0.5% Triton X-100 (Sigma Aldrich). Phosphate-buffered saline/10% fetal calf serum was used for blocking. The AhR antibody (clone RPT9) (Abcam) (diluted 1:500) or the isotype control IgG1-k (Sigma Aldrich) were incubated at 4 1C overnight. Goat anti-mouse IgG (whole molecule)-fluorescein isothiocyanate-coupled secondary antibody (Sigma Aldrich) was used at 1:200. Slides were mounted using CyGEL (Biostatus Limited, Leicestershire, UK). Images were aquired by using a Leica TCS SP2 confocal microscope.
Real-time PCR Total RNA was prepared using the RNeasy system including DNase treatment (Qiagen, Hilden, Germany), and transcribed according to standard protocols. cDNA was prepared using Superscript RNase H -reverse transcriptase (Invitrogen, Paisley, UK) and random hexamers (Sigma Aldrich). For real-time PCR, gene expression was measured in an ABI Prism 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) with SYBR Green Master Mix (Eurogentec, Cologne, Germany) and primers (Sigma Aldrich) at optimized concentrations. Glyceraldehyde 3-phosphate dehydrogenase primers have been described earlier (Carraro et al., 2005 
Immunoblot analysis
For the detection of proteins from cell lysates, cells were lysed in radioimmunoprecipitation assay buffer (10 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate and 0.1% SDS) supplemented with 1 Â complete inhibitor mix (Roche Diagnostics, Grenzach-Wyhlen, Germany) and phosphatase inhibitor cocktails 1 and 2 (Sigma Aldrich). Serum-free conditioned media were concentrated with the centriplus centrifugal filter device YM-3 (3000-Da cutoff; Millipore, Eschborn, Germany). Protein levels were analysed by immunoblot using 20 mg of protein per lane mixed with Laemmli buffer containing b-mercaptoethanol, unless otherwise indicated with the respective antibodies in the concentrations recommended by the manufacturer. Equal protein loading was ascertained by Ponceau S staining. Visualization of protein bands was accomplished using horseradish peroxidase-coupled secondary antibodies (Sigma) and enhanced chemiluminescence (Perbio, Bonn, Germany).
Reporter assay
Dual luciferase/renilla assays were carried out with co-transfection of 150 ng of the respective reporter construct and 20 ng of the renilla reniformis-CMV (pRL-CMV) control plasmid (Promega, Madison, WI, USA). In case of use of three plasmids, 50 ng of the respective reporter construct, 150 ng of the co-plasmid-like pARNT or empty control vector and 20 ng of pRL-CMV were transfected. Luciferase activity was normalized to constitutive renilla activity. The pT81/3 Â DRE reporter construct uses the motif of DRE3 from the CYP enhancer region (Kress et al., 1998) fused in triplicate tandem array into pT81Luc, and was used to assess AhR transcriptional activity. The ARNT-CMV4 construct (Mason et al., 1994) was a kind gift of L Poellinger (Medical Nobel Institute, Karolinska Institute, Stockholm, Sweden). Transcriptional activity mediated by TGF-b1 and TGF-b2 signaling were assessed using the GL3-SBE-4 Luc plasmid, containing four copies of an 8 bp palindrome Smad binding element discovered through an unbiased approach (Zawel et al., 1998) , a reporter plasmid kindly provided by B Vogelstein (Baltimore, MD, USA).
Clonogenic survival assay
The glioma cells (500 per well) were seeded in 6-well plates in Dulbecco's modified Eagle's medium/10% fetal calf serum. Medium was removed after 24 h and cells were treated in serum-free medium with the respective reagents for 24 h, and then kept in medium supplemented with 10% fetal calf serum. When clones were detected by microscopy, medium was removed and number of colonies was quantified using crystal violet staining.
Matrigel invasion assay
Invasion of glioma cells was assessed using matrigel-coated Boyden invasion chambers of a 24-well plate with 8-mm pore size (BD Bioscience). Glioma cells were applied to the upper wells and allowed to transmigrate through the membrane towards conditioned medium derived from NIH-3T3 fibroblasts that was added to the lower wells. At 24 h, migrated cells on the lower side of the membrane were fixed, stained in toluidine blue solution (Sigma Aldrich) and counted in five microscopic high-power fields using a microgrid.
Cell proliferation assay
For the evaluation of cell proliferation, glioma cells were plated in 96-well flat-bottomed plates, and 24 h later treated with serum-free medium plus the respective reagents. The cells were pulse-labeled with 5-bromo-2-deoxyuridine for the last 20 h of treatment and then analysed using the Amersham Cell Proliferation Biotrak ELISA System (GE Healthcare, Buckinghamshire, UK).
Cell cycle analysis
Cell cycle was analysed by flow cytometry (Cyan ADP flow cytometer, Dako, Cambridge, UK, Summit software version 4.3). Adherent cells were collected by trypsin treatment, pooled with the conditioned media containing detached cells, and all cells were fixed in ethanol (70% v/v) and stained with propidium iodide (50 mg/ml) diluted in phosphate buffered saline containing RNase A (100 mg/ml).
Human tissue specimens in vivo expression of AhR was investigated in 23 normal brains, 34 diffuse astrocytomas WHO grade II, 40 anaplastic astrocytomas WHO grade III and 86 primary and 28 recurrent glioblastomas WHO grade IV, using tissue microarrays (Kononen et al., 1998) . For 24 glioblastomas, the infiltration zone was also available for examination. Histopathological grading was carried out by two experienced neuropathologists (GP and JS), according to the current WHO classification (Louis et al., 2007) .
Immunohistochemistry
Immunohistochemistry was carried out on a 4-mm thick paraffin-embedded samples using the Benchmark autostaining system (Ventana, Tucson, AZ, USA) (Schittenhelm et al., 2008) . After blocking of endogenous peroxidase, the polyclonal antibody to AhR (Acris) was applied according to the manufacturer's recommendations (5 mg/ml, 20 min). Binding specificity was controlled by IgG2 isotype controls (DakoCytomation, Hamburg, Germany).
For visualization, I-View horseradish peroxidase-conjugated streptavidin was applied, followed by 3,3-diaminobenzidine tetrahydrochloride/H 2 O 2 . All sections were counterstained with hematoxylin. Using an Olympus Vanox AHBT3 microscope, expression levels were estimated as percentages of positive tumor cells. In addition, overall intensity of nuclear staining was quantified (score 0 absent, score 1 weak, score 2 moderate and score 3 strong).
Statistics
Analysis of significance was carried out using the two-tailed Student's t-test or, where indicated, analysis of variance (JMP 6.0, SAS Software, Cary, NC, USA). For the assessment of in vivo expression levels, the percentages of positive tumor cells and the scores for the relative staining intensities were compared between the various tumor entities using the Kruskal-Wallis test (*Po0.05, **Po0.01, ***Po0.001). For all other experiments showing quantitative data, these are expressed as mean and s.d. The experiments shown were repeated three times with similar results. Analysis of significance was carried out using the two-tailed Student's t-test (Excel, Microsoft, Redmond, WA, USA) (*Po0.05, **Po0.01).
Abbreviations
AhR, aryl hydrocarbon receptor; ARNT, AhR nuclear translocator; BrdU, 5-bromo-2-deoxyuridine; CA-AhR, constitutive active AhR; CI, confidence interval; CYP1A1, cytochrome P450 1A1; DRE, dioxin responsive element; LTBP-1, latent TGF-b-binding protein; PAS, Per-Arnt-Sim; pSmad2, phosphorylated Smad2; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TGF-b, transforming growth factor-b; 3-MC, 3-methylcholanthrene.
